What is BofA Securities's price target for ABOS?

BofA Securities's latest stated price target for Acumen Pharmaceuticals Inc. (ABOS) is $1, from its action on Nov 2, 2026.

What is BofA Securities's rating on ABOS?

BofA Securities rates ABOS Underperform, a bearish rating, as of Nov 2, 2026.

When did BofA Securities last change its view on ABOS?

On Nov 2, 2026, BofA Securities downgrades to Underperform from Buy, price target $1.

Analyst firms · BofA Securities · ABOS

BofA Securities ABOS price target and rating history

Acumen Pharmaceuticals Inc. (ABOS) · Health Care

BofA Securities rates Acumen Pharmaceuticals Inc. (ABOS) Underperform with a $1 price target, as of its latest action on Nov 2, 2026. It has published 4 rating actions on ABOS since July 2021, including 1 upgrade and 1 downgrade.

Current rating: Underperform
Price target: $1
Median target, all firms: Too few
Actions on ABOS: 4

BofA Securities price target on ABOS

BofA Securities price target on ABOS, each point a stated target, July 2021 to November 2026.

Every BofA Securities rating on ABOS

Nov 2, 2026
DowngradeBofA Securities downgrades to Underperform from Buy, price target $1
Jul 20, 2023
ResumeBofA Securities resumes coverage at Buy, price target $9 to $14
Jan 21, 2022
UpgradeBofA Securities upgrades to Buy from Neutral, price target $16 to $14
Jul 26, 2021
InitiateBofA Securities starts coverage at Neutral, price target $20

How other firms rate ABOS

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
BofA Securities	Underperform	$1	Nov 2, 2026
Stifel	Hold	$1	Oct 30, 2026

Questions about BofA Securities and ABOS

What is BofA Securities's price target for ABOS?: BofA Securities's latest stated price target for Acumen Pharmaceuticals Inc. (ABOS) is $1, from its action on Nov 2, 2026.
What is BofA Securities's rating on ABOS?: BofA Securities rates ABOS Underperform, a bearish rating, as of Nov 2, 2026.
When did BofA Securities last change its view on ABOS?: On Nov 2, 2026, BofA Securities downgrades to Underperform from Buy, price target $1.

All BofA Securities ratings ABOS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.